A number of pharmaceutical companies presented data on some of their new hepatitis C drugs at a recent meeting of the American Association for the Study of Liver Diseases.
In an interview with the Wall Street Journal, Dr. Kathleen Squires, director of the Division of Infectious Diseases at Jefferson, says that Vertex and Merck’s current treatments have improved cure rates to as much as 75 percent, up from the 50 to 60 percent for patients treated with previous therapies. Adding that while much improved, even a 25 percent failure rate is high because the chances of being cured decrease after failing treatment as the virus grows resistant.
To learn more, read: “Gilead Sciences Still Seen as Frontrunner in Hepatitis C Drug Race.”
Publication: Wall Street Journal
No comments yet.